David Mahoney Biography and Net Worth



David L. Mahoney is a private investor who has served as a member of our Board since July 2004. From 1999 to 2001, Mr. Mahoney served as co-Chief Executive Officer of McKesson HBOC, Inc., a healthcare supply management and information technology company, and as Chief Executive Officer of iMcKesson LLC, a healthcare management and connectivity company. He joined McKesson Corporation in 1990 as Vice President for Strategic Planning. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company, a management consulting firm, where he worked from 1981 to 1990. Mr. Mahoney has served on the board of directors of Adamas Pharmaceuticals, a publicly traded pharmaceutical company, since 2011, including as Chairman, and chair of the Compensation Committee and a member of the Nominating and Governance Committee. Mr. Mahoney also served as a member of the Audit Committee of Symantec from 2003 to 2011 and as a member of the board of directors from 2003 to 2019. He also serves on the board of directors of several privately held organizations including San Francisco Museum of Modern Art, Mercy Corps and Mount Holyoke College and is a Trustee of the Schwab/Laudus Family of Funds. Mr. Mahoney received his B.A. from Princeton University and his M.B.A. from Harvard University.

What is David L. Mahoney's net worth?

The estimated net worth of David L. Mahoney is at least $624,950.04 as of August 14th, 2023. Mr. Mahoney owns 11,297 shares of Corcept Therapeutics stock worth more than $624,950 as of November 14th. This net worth estimate does not reflect any other assets that Mr. Mahoney may own. Learn More about David L. Mahoney's net worth.

How do I contact David L. Mahoney?

The corporate mailing address for Mr. Mahoney and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on David L. Mahoney's contact information.

Has David L. Mahoney been buying or selling shares of Corcept Therapeutics?

David L. Mahoney has not been actively trading shares of Corcept Therapeutics during the last quarter. Most recently, David L. Mahoney sold 25,000 shares of the business's stock in a transaction on Monday, August 14th. The shares were sold at an average price of $30.95, for a transaction totalling $773,750.00. Following the completion of the sale, the director now directly owns 11,297 shares of the company's stock, valued at $349,642.15. Learn More on David L. Mahoney's trading history.

Who are Corcept Therapeutics' active insiders?

Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.

Are insiders buying or selling shares of Corcept Therapeutics?

In the last year, insiders at the biotechnology company sold shares 32 times. They sold a total of 269,472 shares worth more than $7,991,445.07. The most recent insider tranaction occured on November, 11th when Director Daniel N. Swisher, Jr. sold 2,200 shares worth more than $131,736.00. Insiders at Corcept Therapeutics own 20.5% of the company. Learn More about insider trades at Corcept Therapeutics.

Information on this page was last updated on 11/11/2024.

David L. Mahoney Insider Trading History at Corcept Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/14/2023Sell25,000$30.95$773,750.0011,297View SEC Filing Icon  
7/19/2017Sell23,006$12.50$287,575.00View SEC Filing Icon  
7/18/2017Sell6,091$12.50$76,137.50View SEC Filing Icon  
7/13/2017Sell6,994$12.50$87,425.00View SEC Filing Icon  
7/12/2017Sell6,510$12.50$81,375.00View SEC Filing Icon  
7/8/2015Sell33,828$5.74$194,172.72View SEC Filing Icon  
See Full Table

David L. Mahoney Buying and Selling Activity at Corcept Therapeutics

This chart shows David L Mahoney's buying and selling at Corcept Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corcept Therapeutics Company Overview

Corcept Therapeutics logo
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $55.32
Low: $54.69
High: $57.50

50 Day Range

MA: $45.70
Low: $34.10
High: $59.60

2 Week Range

Now: $55.32
Low: $20.84
High: $61.66

Volume

209,268 shs

Average Volume

1,183,672 shs

Market Capitalization

$5.80 billion

P/E Ratio

43.91

Dividend Yield

N/A

Beta

0.45